Oxycodone controlled release - Elite Pharmaceuticals

Drug Profile

Oxycodone controlled release - Elite Pharmaceuticals

Alternative Names: ELI-154; once-a-day oxycodone - Elite Pharmaceuticals; oxycodone CR - Elite Pharmaceuticals; OxyQD™

Latest Information Update: 10 Jun 2015

Price : $50

At a glance

  • Originator Elite Pharmaceuticals
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 16 Feb 2012 Oxycodone controlled release is still in phase II trials for Pain in USA
  • 18 Nov 2010 Development is ongoing in USA (PO)
  • 18 Nov 2010 Oxycodone controlled release - Elite Pharmaceuticals is still available for licensing in Europe. http://www.elitepharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top